Emerging at the UK, retatrutide, a novel compound , is sparking considerable excitement within the scientific community regarding its promise for physique management . This dual GIP and GLP-1 agent agonist appears to provide a considerable improvement over current therapies, showing promising results in early clinical assessments. Researchers sugge